Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence ; volume:15 ; number:1 ; day:18 ; month:9 ; year:2023 ; pages:1-14 ; date:12.2023
Genome medicine ; 15, Heft 1 (18.9.2023), 1-14, 12.2023
- Creator
-
Zhang, Shuming
Yuan, Long
Danilova, Ludmila
Mo, Guanglan
Zhu, Qingfeng
Deshpande, Atul
Bell, Alexander T. F.
Elisseeff, Jennifer
Popel, Aleksander S.
Anders, Robert A.
Jaffee, Elizabeth M.
Yarchoan, Mark
Fertig, Elana J.
Kagohara, Luciane T.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13073-023-01218-y
- URN
-
urn:nbn:de:101:1-2024020908075570630651
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zhang, Shuming
- Yuan, Long
- Danilova, Ludmila
- Mo, Guanglan
- Zhu, Qingfeng
- Deshpande, Atul
- Bell, Alexander T. F.
- Elisseeff, Jennifer
- Popel, Aleksander S.
- Anders, Robert A.
- Jaffee, Elizabeth M.
- Yarchoan, Mark
- Fertig, Elana J.
- Kagohara, Luciane T.
- SpringerLink (Online service)
Other Objects (12)
Kombinationstherapie mit Cabozantinib plus Nivolumab : Erstlinienbehandlung beim fortgeschrittenen Nierenzellkarzinom
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Cabozantinib : Cabozantinib in der Behandlung des fortgeschrittenen Nierenzellkarzinoms
Nivolumab (NSCLC, neoadjuvant) : Addendum zum Projekt A23-74 (Dossierbewertung)
Nivolumab (NSCLC, neoadjuvant) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Simultaneous Tumor Shrinkage and Bronchial Perforation Induced by Nivolumab plus Cabozantinib Combination Therapy in a Patient with Collecting Duct Carcinoma
Postoperative recurrence in locally advanced rectal cancer: how does neoadjuvant treatment affect recurrence pattern?
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
Kombinationstherapie mit Cabozantinib plus Nivolumab : Erstlinienbehandlung beim fortgeschrittenen Nierenzellkarzinom
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Cabozantinib : Cabozantinib in der Behandlung des fortgeschrittenen Nierenzellkarzinoms
Nivolumab (NSCLC, neoadjuvant) : Addendum zum Projekt A23-74 (Dossierbewertung)
Nivolumab (NSCLC, neoadjuvant) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Simultaneous Tumor Shrinkage and Bronchial Perforation Induced by Nivolumab plus Cabozantinib Combination Therapy in a Patient with Collecting Duct Carcinoma
Postoperative recurrence in locally advanced rectal cancer: how does neoadjuvant treatment affect recurrence pattern?
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
Kombinationstherapie mit Cabozantinib plus Nivolumab : Erstlinienbehandlung beim fortgeschrittenen Nierenzellkarzinom
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Cabozantinib : Cabozantinib in der Behandlung des fortgeschrittenen Nierenzellkarzinoms
Nivolumab (NSCLC, neoadjuvant) : Addendum zum Projekt A23-74 (Dossierbewertung)
Nivolumab (NSCLC, neoadjuvant) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Simultaneous Tumor Shrinkage and Bronchial Perforation Induced by Nivolumab plus Cabozantinib Combination Therapy in a Patient with Collecting Duct Carcinoma
Postoperative recurrence in locally advanced rectal cancer: how does neoadjuvant treatment affect recurrence pattern?
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma